Amostomig Biosimilar – Anti-Leukocyte surface antigen CD47;PDL1 mAb – Research Grade

Description of Amostomig Biosimilar - Anti-Leukocyte surface antigen CD47;PDL1 mAb - Research Grade

“

The Structure of Amostomig Biosimilar – Anti-Leukocyte surface antigen CD47;PDL1 mAb – Research Grade

Amostomig Biosimilar – Anti-Leukocyte surface antigen CD47;PDL1 mAb – Research Grade is a therapeutic antibody that has been developed to target the surface antigens CD47 and PDL1. This biosimilar is a monoclonal antibody, meaning it is made up of identical immune cells that have been cloned from a single parent cell. It is designed to mimic the structure and function of the original therapeutic antibody, while also providing a more cost-effective option for patients.

The antibody is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The heavy chains contain a constant region and a variable region, while the light chains only have a variable region. The variable regions are responsible for binding to the specific targets, CD47 and PDL1, on the surface of leukocytes. This binding is crucial for the therapeutic activity of the antibody.

The Activity of Amostomig Biosimilar – Anti-Leukocyte surface antigen CD47;PDL1 mAb – Research Grade

The main activity of Amostomig Biosimilar – Anti-Leukocyte surface antigen CD47;PDL1 mAb – Research Grade is to block the interaction between CD47 and PDL1. CD47 is a protein that is found on the surface of many types of cells, including leukocytes. It acts as a “”don’t eat me”” signal, preventing the immune system from attacking these cells. PDL1, on the other hand, is a protein found on the surface of cancer cells and other cells in the body. It interacts with PD1 receptors on immune cells, inhibiting their activity and allowing cancer cells to evade detection and destruction by the immune system.